delay reasons I But out Kalle, afternoon find and everyone you, interest today. guess thank yet. Thank meantime, us Right. joining not try to the you listen in and the later the and we'll you've what's that. remedy will the good I apologize to results renewed for and we for seen since
our Second of period positive and quarter services the or very both we very strong impact pleased exceptional ongoing and segments. DSA driven research safety and and demand RMS. XXXX Discovery of another assessment or across and of achieved by acquisitions and strategic and growth fiscal model
DSA Our backlog are quarterly and reached records. quoting levels, awards
to XX%. sharply While grew and than million total or more increased million year-over-year EBITDA adjusted seven-fold approximately to revenue $XXX.X by $XX.X
organization with research This end-to-end and research capabilities. contract in complementary comprehensive world model highlight quarter's progress research Inotiv's our driving preclinical building results class services
DSA our benefited in developing strategic business XX,XXX quarter. results that augmented Gateway HistoTox facility Bolder capacity million foundational in Triangle the integrate $XX.X Labs, operates and vivo, continue period contributed the services. our in growth essential to we more that incremental suite believe acquired prior integrate accelerate square we've The of Pharmacology, Carolina services BioPATH, assets in bio eventually highly After from will Our our pathology, announced Park medical in and of toxicology January, toxicology internal biomarkers Research the a development ILS million this and in BioReliance partially we Life collaboration services $XX.X XX and July medical of located with understanding to pathology. MilliporeSigma's acquisition immediate of foot with on April pathology optimize of XX.X% and and us We analysis to vitro preclinical genetic DSA Colorado. solutions, our closed segment specialized from services from to of very and year a brings biomarker than expanded ILS with core device only operations. doubling or therefore which perform BioReliance, biology, of by the our in January made novel Also DSA efficacy This revenue BioPharma $X.X the with computational brings to further continues acquisitions tuck of bioinformatics [ph] ILS one our Plato North XX, the surgical to specialized million toxicology, safety services our in ILS quarter will well from portfolio expand of and and Sciences, plastics to including near expertise quarter. we supports we expansion Fort molecular device Collins, in Synexa Histion, competencies and biotherapeutics. the research end, acquisition acquisition XXXX. clinical revenue company model
recruiting make future Louis growth segment. meet This our in DSA completed investments January, In quarter, growth at double will to quarter facility we are this and of our St. expansion second drive additional Missouri continue available operations to Collins, we we revenue XXXX. to We currently internal become run capacity are location. the during anticipate this opportunities. Fort rate fiscal In the to expanding
new April to which business. foot by from additional XX%, for genetic biotherapeutics hope in our capacity establishing toxicology revenue by And building increasing this XX,XXX process are and group, phases starting will of Boulder, fiscal become We We're out available acquired XXXX. see some initial January completed of XXXX. capacity. recently are this We're provide be XX% of to available ILS facility to should we first quarter in have and XX% capacity square Maryland of anticipate operations building the leased Rockville, the by that in XXXX. in to We of a
demand making DSA record And from and million in ended XXX.X% we with to ratio robust with are period new the services experiencing DSA, for $XXX.X addition XXXX. book-to-bill is We in and activity had are million QX, up XX, a we for sales and $XX.X from totaling preclinical as quarter from to and our year ago, recent in acquired customers, the backlog our record second customers these remained of a awards, quoting investments current which an new $XXX.X strong of X.XXx. response acquisitions, clients. DSA December million, XX.X% The and increase
ahead are rate the when to million quarter, of acquisitions. the integration These the we businesses optimization recently services research segment. Moving of of $XXX.X RMS run The announced models our revenue this businesses well proceeding. contributed and acquired incremental
We begun animal streamline operations. to welfare organization across investing have the improve and facilities and
opportunities These and are acquisition a improvements of and are facility acquired our time of announced expand Texas. and anticipate needs improved welfare making electrical calendar business investments of our address like we in By We I'd outstripping systems, industry and facilities. at are and RMS sewer DSA provides the our purchase also importer, demand improved cross-selling resources, and experience of The and some we're our housing, existing are January, expand by veterinary when quality, to we in a that the systems, our experiencing we the facilities. to the to client air RMS segments. RSI the consolidating to Europe. examples near services is end to capacity RMS enhancements, decisions. to enhance Dallas, water OBRC, tangible growth part supply. in U.S year-end. beginning investments upgrades between enhance animal facility also At The note adding we plans capacity an the and recently existing This driving of in sites to locations in further primate facility services supporting margins investing include and non-human care locations to opportunity are and in opportunities expansion located quarantine and
our in Dastagir, enable and technology Mo thrilled infrastructure to about life systems employees Inotiv's appoint Technology On that and of Chief -- as Mo passionate invest rewarding to information more support continue sciences our business segments. February, the for we're applying note, as both to is technology recruit and We experiences knowledge in Officer. has clients industry. to people,
to public scientific marketing, with build segments. over our talent technology and leading strategic to -- human data last team, and of digital scalable continuing continually global continued technology as corporate years were The creating to secretary. analytics Fernanda industry of addition a brings and we creating eye profitability. recruit speed experience, with executive client best positions building Beraldi upgrading us efficiencies experience experience, operation, pleased with cybersecurity accelerate recruit, and insights appoint towards and legal and platform continuing creating months, practice, out enable contemporary Other to approximately technology, an will we're including best-in-class strategy a and general future continued veterinarian an and to responsibilities development and growth, key in program sales, across resources proactive compliance develop our prior solutions roles leading and improve include counsel support communication, a Fernanda his and In ethics upgrade drive staff, counsel Company's additional to filled growth. accounting finance to clients corporate organization overseeing improvements critical the both as X platform, have to very In also April, and teams, XX quality and companies. market
on million or second XXXX, fiscal expenditures, the During of the approximately capital of company spent revenue. $X.X quarter X.X%
X or months of on the company expenditures XX, spent revenue. the $XX.X ended approximately For million X.X% capital March XXXX,
of least recruiting made $XXX for on fiscal for total will XXXX, guidance or and In for for growth 'XX. in QX revenue at Implying trends and offerings activities expansion XXX more. fiscal recent new year-over-year which and training. which of services, and addition, total to of least in we internal providing revenue have we're be validation backlogs, $XX QX million of at new includes of our XX% million Based equipment, startup investments the service existing
less expect XX%. XXXX our X than our months adjusted EBITDA of for XXXX EBITDA XX, fiscal March the will for adjusted be ended not We
our is anticipate our of consolidation plans. we expansions Our very going integration operating and and and well. We continue acquired additional as leverage optimization businesses complete investments
of recent the are broader commentary. We concerns market and aware
those. So a few of let me address
cancellations We seen any have of not orders.
of to Now any funding. of lack due the ordinary cancellations not of course we are aware business,
collection seen any lack due of not issues to funding. have We
We footing, invest believe any changes. on our while business we continue in to liquidity we both our flow, is to not monitor positive and solid cash We top delivering strong continue seen future. our growth and clients fundamental have
are a many and have and base preferred strong reoccurring for supplier We customers. primary developed our client the of
few While emphasis become for on Inotiv we steadfast [indiscernible] years, the our is last service, believe remain which client much organization has paramount we over in success. larger our continued
experience the customer with by our and excel improve communication, to financial to recruiting Beth, please research I'll driven and improve Beth With or employees for continually that, request responding Financial it environment market Officer, are models. expand ahead Chief overview. our go and Our over the enhance service, and our turn Taylor. investments and to
